Références
- Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Kim, Min Seo et al.
The Lancet Global Health, Volume 11, Issue 10, e1553 - e1565
- Fujihara M, Takahara M, Sasaki S, et al. Angiographic Dissection Patterns and Patency Outcomes After Balloon Angioplasty for Superficial Femoral Artery Disease. J Endovasc Ther. 2017;24(3):367-375. doi:10.1177/1526602817698634
- Jaff MR, Rosenfield K, Scheinert D, et al. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial. Am Heart J. 2015;169(4):479-485. doi:10.1016/j.ahj.2014.11.016
- Krankenberg H, Tübler T, Ingwersen M, et al. Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial. Circulation. 2015;132(23):2230-2236. doi:10.1161/CIRCULATIONAHA.115.017364
- Feldman DN, Armstrong EJ, Aronow HD, et al. SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. Catheter Cardiovasc Interv. 2018;92(1):124-140. doi:10.1002/ccd.27635
- Wu Z, Huang Q, Pu H, et al. Atherectomy Combined with Balloon Angioplasty versus Balloon Angioplasty Alone for de Novo Femoropopliteal Arterial Diseases: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Eur J Vasc Endovasc Surg. 2021;62(1):65-73. doi:10.1016/j.ejvs.2021.02.012
- Fan W, Lu S, Tan J, et al. Midterm Results of Drug-Coated Balloon Alone or Combined with Rotarex Thrombectomy Device for Treatment of Subacute Femoropopliteal Artery Thrombotic Occlusion. Ann Vasc Surg. 2023;92:240-248. doi:10.1016/j.avsg.2022.11.019
- Salisbury AC, Li H, Vilain KR, et al. Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial. JACC Cardiovasc Interv. 2016;9(22):2343-2352. doi:10.1016/j.jcin.2016.08.036
- Pan T, Tian SY, Liu Z, Zhang T, Li C, Ji DH. Combination of RotarexⓇ S Rotational Atherothrombectomy and Drug-Coated Balloonangioplasty for Femoropopliteal Total In-Stent Occlusion. Ann Vasc Surg. 2022;80:213-222. doi:10.1016/j.avsg.2021.08.058
- Bailey SR, Beckman JA, Dao TD, et al. ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine. J Am Coll Cardiol. 2019;73(2):214-237. doi:10.1016/j.jacc.2018.10.002
- Scheinert D, Schmidt A, Zeller T, et al. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease. J Endovasc Ther. 2016;23(3):409-416. doi:10.1177/1526602816644592
- Krankenberg H, Tübler T, Ingwersen M, et al. Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial. Circulation. 2015;132(23):2230-2236. doi:10.1161/CIRCULATIONAHA.115.017364
- Baumann F, Fust J, Engelberger RP, et al. Early recoil after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia. J Endovasc Ther. 2014;21(1):44-51. doi:10.1583/13-4486MR.1
Rejoignez notre communauté et repensez votre stratégie de traitement de la PAD
Ne manquez pas cette occasion ! Acceptez de recevoir nos communications et bénéficiez d'un accès exclusif à des données cliniques, des événements spéciaux et du contenu spécialement sélectionné pour les spécialistes des maladies artérielles périphériques.